Attention ESSA Pharma Investors: Important Class Action Notice
Faruqi & Faruqi, LLP, a prominent securities litigation firm, is advising investors who have incurred losses of over $50,000 in ESSA Pharma to reach out directly to discuss their legal options.
Are you one of the investors who faced setbacks in your investment in ESSA Pharma? If your losses exceeded $50,000 within the period leading up to crucial company announcements, it’s essential to connect with Faruqi & Faruqi partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) to learn about potential legal recourse.
Details of the Pending Class Action Lawsuit
Currently, Faruqi & Faruqi is investigating significant claims against ESSA Pharma Inc. (“ESSA” or the “Company”) (NASDAQ: EPIX). The firm would like to remind investors about the critical deadline of March 25, 2025, for those interested in becoming the lead plaintiff in a federal securities class action filed against the Company.
Understanding the Allegations Against ESSA Pharma
This lawsuit surfaces from allegations that ESSA and its executives misled investors regarding key data on their drug, masofaniten, which was tested alongside enzalutamide. Claims suggest that the company overstated the drug's effectiveness, leading investors to have unrealistic expectations.
The Impact of Recent Company Announcements
On October 31, 2024, ESSA announced the termination of its Phase 2 trial concerning masofaniten’s efficacy when combined with enzalutamide for prostate cancer treatment. An interim review of the data indicated that the combination did not provide the anticipated benefits, which subsequently resulted in a 73.08% drop in stock price, closing at $1.40 per share, reflecting a loss of $3.80 per share on November 1, 2024.
Class Action Participation and Implications
In such class actions, the lead plaintiff is typically the one with the most substantial financial stake in the claims made, and their role encompasses overseeing the litigation process on behalf of all class members. As a potential class member, you can engage with the court to seek candidacy for lead plaintiff, although participation is not mandatory, and you remain eligible for any recovery regardless of your active involvement.
Faruqi & Faruqi strongly encourages anyone who may have relevant information regarding ESSA’s conduct, including whistleblowers and former employees, to come forward and share their insights with the firm.
For further details on joining the ESSA Pharma class action, visit Faruqi & Faruqi’s dedicated page at www.faruqilaw.com/EPIX or directly contact partner Josh Wilson at the numbers provided.
Get Updates and Stay Informed
To keep up with the latest updates and news regarding this case and the firm’s various efforts, follow Faruqi & Faruqi across their social media platforms.
Frequently Asked Questions
What is the class action lawsuit about?
The class action lawsuit involves allegations against ESSA Pharma for misleading statements regarding the efficacy of its treatment, masofaniten.
How can I find out if I'm eligible to participate?
If you suffered losses over $50,000 in ESSA Pharma, you may be eligible. Contact Faruqi & Faruqi for more guidance.
What is the deadline to become a lead plaintiff?
The deadline to seek lead plaintiff status is March 25, 2025.
What recent events affected ESSA Pharma's stock price?
ESSA announced the termination of its Phase 2 clinical trial, which resulted in a significant drop in its stock price due to disappointing findings.
Who should I contact for more information?
For inquiries, reach out to James (Josh) Wilson at Faruqi & Faruqi using the provided contact numbers.
